Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | CBFB | Q13951 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650763 | 0.88 | FLT3 (0.51) | FLT3EGLN1CBFBRHOCRHOA | |
| SCHEMBL5651375 | 0.86 | FLT3 (0.50) | FLT3EGLN1CBFBRHOCRHOA | |
| SCHEMBL5651705 | 0.86 | FLT3 (0.50) | FLT3EGLN1CBFBRHOCRHOA | |
| SCHEMBL5647974 | 0.86 | HDAC6 (0.50) | FLT3CBFBSIGMAR1PRSS12KDM4E | |
| SCHEMBL5652827 | 0.85 | FLT3 (0.51) | FLT3P2RY14OPRD1SIGMAR1MAPK8 | |
| SCHEMBL5649037 | 0.84 | METAP2 (0.50) | FLT3CBFBMAPTMRGPRX4 | |
| SCHEMBL5653300 | 0.84 | FLT3 (0.72) | FLT3NPBWR1CHEK2 | |
| SCHEMBL5651231 | 0.83 | CD274 (0.55) | KDM4EALDH1A1 | |
| SCHEMBL5650711 | 0.83 | FLT3 (0.47) | FLT3CBFBRHOCRHOAMRGPRX4 | |
| SCHEMBL5650457 | 0.82 | FLT3 (0.44) | FLT3EGLN1CBFBP2RY14OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885EGLN1 594/4885CBFB 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.